governance and ethics

As a private UK company infirst Healthcare Ltd is not listed on any public stock exchange. Its shareholders comprise Biocopea Ltd (an entity within the SEEK Group) and five investment funds, four of which are represented by Invesco Perpetual Asset Management (one of the UK’s largest and most successful independent investment funds).

The business is managed by a Leadership team with many decades of industry experience. This team strives to manage the business through the development and application of consistent and cohesive policies, guidelines, processes and decision making authorities. The Leadership team is accountable to the Board of Directors, which is chaired by Dr Lynn Drummond, formerly a managing director at N.M. Rothschild investment bank, who also has considerable experience in the healthcare industry.

Board members

Executive directors

Manfred Scheske
Manfred Scheske
Chief Executive Officer
Lived and worked in Germany, USA, UK

Manfred is Chief Executive Officer and a member of the Board of infirst Healthcare. Manfred was latterly President of GlaxoSmithKline's Consumer Health business across Europe, having previously led the North-American and German businesses. He enjoyed 25 highly successful years at GSK and its legacies and has also given long service to industry trade association boards in both the US and Europe. Manfred studied Business and Economics at The University of Cologne.

Andrew Waters
Chief Financial Officer
Lived and worked in Netherlands, Denmark, USA, UK

Andrew joined infirst Healthcare as Chief Financial Officer and a member of the Board in January 2013. He is a chartered accountant with more than 20 years' experience in the pharmaceutical and consumer healthcare industries. Andrew is a Physics graduate of Imperial College London and worked at GlaxoSmithKline for over 16 years, in a series of senior financial roles. Andrew started his career at Price Waterhouse Coopers in London.

Andrew Waters

Non-executive directors

Kim Duncan
Non-Executive Director
Lived and worked in US, Japan, UK, Europe and Africa

Kim is a Non-Executive Director of infirst Healthcare. He began his career as a trader at Goldman Sachs in 1987, moving to Nomura, Credit Suisse and Mizuho, leading teams conducting principal investment activities in which the firms' capital was invested directly for their own account. His major transactions include the acquisitions of Inntrepreneur Pub chain, Angel Trains, AT&T Capital and Stenvalvet AB. Kim has extensive experience in structured finance, leveraged finance and credit derivatives trading. He is a graduate of Yale University and sits on the boards of other early stage ventures including SEEK, Curemark LLP, Pharmajet Inc, Spatial View Inc., and Ignite Gaming Technologies. In 2010, Kim co-founded the Rush Foundation, which aims to fund disruptive ideas against HIV in sub-Saharan Africa.

Carol L’Heveder
Non-Executive Director

Carol is a financial services / M&A lawyer (Linklaters) and was formerly general counsel (wealth management) EMEA for Merrill Lynch and Head of Legal EMEA at State Street Bank & Trust. She has significant experience in running legal teams and business units, leading multidisciplinary projects and managing multinational acquisitions, restructuring & joint ventures.

As a regulatory expert with a strong track record as a problem solver, her current focus is on advising Invesco on its Brexit strategy and implementing the FCA changes to fund governance.

Carol has gained significant corporate governance experience, having been a board member of State Street Luxembourg SA and State Street Bank Italy and member of various group executive committees at Maitland, State Street and Merrill Lynch.

Carol is currently executive chair of IVCO Management Limited, a company which owns and manages the freehold of Iverna Court.

Gregory A. Stoloff
Non-Executive Director
Lived and worked in Australasia, USA and Europe

Gregory is Non-Executive Director of infirst Healthcare and Chief Executive Officer of SEEK (formerly known as PepTcell) which he founded in 2004, after a distinguished 20 year career in investment banking at Deutsche Bank and UBS. He has worked on numerous mergers, acquisitions and structured finance deals in the healthcare industry, including mergers by GlaxoSmithKline, Aventis and Pfizer. Gregory has also worked in project finance for major pharmaceutical company clients such as Roche, Merck and Novartis. He has a wealth of experience in advising and working with medical research companies across Australasia, USA and Europe.

Gregory is a qualified Chartered Accountant and has spent many years researching scientific medical issues, specifically related to the immune system. He has had several scientific papers published, many specialising in the area of research into peptides and is listed as an inventor in numerous patents for cancer, HIV, mosquito-borne diseases and influenza.

25% of British people - wait until something is "seriously wrong" before seeing their GP
25% of British people

wait until something is "seriously wrong" before seeing their GP